FluidForm Presents Data Demonstrating Performance of its Cardiac Drug Discovery Platform
SUDBURY, Mass. (PRWEB) March 28, 2023 -- FluidForm, a leader in manufacturing human tissue for drug discovery, announced the presentation of data from its Cardiac Drug Discovery Platform (CDDP) last Thursday at the Biomedical Engineering Society Advanced BioManufacturing meeting in Hyattsville, MD. In his keynote presentation, FluidForm’s CTO, Professor Adam Feinberg, shared data that demonstrates the hallmarks of engineered human cardiac tissue, including highly aligned cells at true physiologic density, with reproducible calcium transients and fast conduction velocity. When subjected to the β-adrenergic receptor agonist isoproterenol, tissue showed native-like positive chronotropic and inotropic responses, a combination of responses that is not typically observed in 2D monolayer models or standard 3D engineered heart tissue approaches. The study, FRESH™ 3D bioprinted cardiac tissue, a bioengineered platform for in-vitro toxicology and pharmacology, was conducted by scientists at FluidForm and Merck & Co., and published to the preprint server bioRxiv.
“FluidForm’s CDDP is the first tool to give actionable, translationally relevant signals at the critical juncture of lead selection and lead optimization.”
“Cardiac drug discovery has been a particular challenge for many years,” said Feinberg, FluidForm’s CTO and Professor in the Departments of Biomedical Engineering and Materials Science and Engineering at Carnegie Mellon University. “Existing in-vitro models have not provided the information needed to identify the best drug candidates for human disease, and animal models fail to capture the physiology of the human heart. FluidForm’s CDDP is the first tool to give actionable, translationally relevant signals at the critical juncture of lead selection and lead optimization.”
FluidForm’s CDDP provides its pharmaceutical partners with data predictive of how a drug will affect cardiac tissue long before a drug is ever studied in humans. These critical insights can help decrease the time it takes to develop new drugs, which will also decrease costs. As global governments work with companies to decrease reliance on ineffective animal models, solutions such as FluidForm’s CDDP are becoming a critical tool in the pharmaceutical discovery process.
About FluidForm
FluidForm is revolutionizing the drug discovery process with our manufactured human tissue. Our drug discovery platforms are based on our patented FRESH™ 3D printing technology, the most advanced biofabrication platform in the world, as published in Science. The company has developed translationally relevant tissue that can dramatically improve the speed and success rate of drug discovery, with initial applications in cardiovascular. FluidForm is in the Boston area.
Rickey Kallicharan, FluidForm, 1 609.468.0604
